Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia

NCT00276809 is registered in ClinicalTrials.gov with German CLL Study Group as lead sponsor.

NCT NCT00276809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Lead sponsor
German CLL Study Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2001
Completion date
September 30, 2004
Enrollment
30 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia